Nicolás Merchante
- Hepatology top 0.5%
- Epidemiology top 2%
- Infectious Diseases top 5%
- Emergency Medicine top 5%
- Virology top 5%
- Co-authors
- Juan A. PinedaJuan Macı́asAntonio RiveroJosé Antonio López MiraJesús Gómez‐MateosJosé Ángel García-GarcíaFernando LozanoAntonio Rivero‐Juárez
- Topics
- Liver Disease Diagnosis and Treatment (44 papers)Hepatitis C virus research (44 papers)Liver Disease and Transplantation (17 papers)
- Partner nations
- SpainUnited StatesChile
In The Last Decade
Nicolás Merchante
64 papers receiving 1.3k citations
Peers
Comparison fields: 5 of 77
- Hepatology 1.1k
- Epidemiology 980
- Infectious Diseases 406
- Emergency Medicine 181
- Virology 89
Countries citing papers authored by Nicolás Merchante
This map shows the geographic impact of Nicolás Merchante's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicolás Merchante with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicolás Merchante more than expected).
Fields of papers citing papers by Nicolás Merchante
This network shows the impact of papers produced by Nicolás Merchante. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicolás Merchante. The network helps show where Nicolás Merchante may publish in the future.
Co-authorship network of co-authors of Nicolás Merchante
This figure shows the co-authorship network connecting the top 25 collaborators of Nicolás Merchante. A scholar is included among the top collaborators of Nicolás Merchante based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicolás Merchante. Nicolás Merchante is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical Trial | 25 |
| 3 | 9 | |
| 4 | 15 | |
| 5 | 10 | |
| 6 | 3 | |
| 7 | 11 | |
| 8 | 10 | |
| 9 | 9 | |
| 10 | 5 | |
| 11 | 12 | |
| 12 | 39 | |
| 13 | 8 | |
| 14 | 44 | |
| 15 | 51 | |
| 16 | 7 | |
| 17 | 6 | |
| 18 | 4 | |
| 19 | 33 | |
| 20 | 128 |
About Nicolás Merchante
Nicolás Merchante is a scholar working on Hepatology, Epidemiology and Infectious Diseases, having authored 64 papers that have together received 1.4k indexed citations. Recurring topics across this work include Liver Disease Diagnosis and Treatment (44 papers), Hepatitis C virus research (44 papers) and Liver Disease and Transplantation (17 papers). The work is most often cited by research in Hepatology (1.1k citations), Epidemiology (980 citations) and Infectious Diseases (406 citations). Nicolás Merchante has collaborated with scholars based in Spain, United States and Chile. Frequent co-authors include Juan A. Pineda, Juan Macı́as, Antonio Rivero, José Antonio López Mira, Jesús Gómez‐Mateos, José Ángel García-García, Fernando Lozano, Antonio Rivero‐Juárez, Dolores Merino and Francisco Téllez. Their work appears in journals such as PLoS ONE, Hepatology and Clinical Infectious Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.